Why is Coloplast stock declining today?

Coloplast’s Q4 EBIT was DKK 1,848 million, below analyst consensus of roughly DKK 2,000–2,018 million, while its EBIT margin fell to about 25% from 28% a year earlier; organic revenue growth was 5%, broadly in line with estimates. FY 2026/27 guidance calls for an EBIT margin of around 25% in constant currencies and organic growth of 5–7%, and the company lowered its 2030 Wound & Tissue Repair growth ambition from around double-digit to mid-single digit. Morgan Stanley cut its price target to DKK 418 from DKK 454 and Oddo to DKK 412 from DKK 413; shares were down 2.3%, trading at DKK 470.2 after reaching a session low of DKK 447, versus a previous close of DKK 481.4.

Analysis

The key issue is not a single-quarter cost overrun but whether Coloplast’s earnings power has reset lower: flat-to-weaker margin guidance plus a lower long-term growth ambition makes a near-term “temporary ramp cost” explanation less persuasive. If Portugal costs fade but biologics reimbursement pressure persists, any recovery could be smaller than investors expect. Conversely, raw-material, freight and HUF effects may ease; the stock’s reaction should hinge on evidence that core margins stabilize, not revenue growth alone.

For competitors such as Convatec and Smith+Nephew, the read-through is conditional: if the US reimbursement change is category-wide, it may pressure exposed biologics economics; if Coloplast-specific, rivals could gain share. Verify exposure before expressing that relative-value trade. The broader risk is that investors extrapolate Coloplast’s reset to wound-care peers without distinguishing reimbursement mix.

Near term, repeated profit misses and no guided margin rebound support downside risk, but the share-price decline alone does not establish attractive short entry or valuation. Over 1–3 months, watch segment growth, reimbursement realization, and quarterly margin commentary; over 6–18 months, the test is whether manufacturing efficiencies offset structural biologics weakness. A meaningful reversal would require margin stabilization or better-than-guided growth, while further segment downgrades would reinforce multiple-compression risk.

Key Decisions for Investors

• Keep COLO.B underweight pending evidence of margin stabilization; do not add solely on the pullback. Reassess after the next results and any quantified update on Portugal ramp costs, FX, and input-cost pass-through.
• Treat a short COLO.B position as a conditional idea, not a high-conviction trade: initiate only if subsequent guidance or results show margins below the ~25% constant-currency framework or further biologics deterioration. Falsifier: sequential margin stabilization with no downgrade to the 5–7% growth outlook.
• Avoid a blind short of wound-care peers. Before considering a COLO.B-versus-Convatec or Smith+Nephew relative-value position, verify each company’s exposure to the US reimbursement change, segment mix, and valuation; the policy spillover may be uneven.
• Monitor the next 1–3 months for segment-level growth and margin disclosure, reimbursement effects, and evidence that freight/raw-material and HUF pressures are easing. These details are needed to distinguish temporary cost drag from a durable earnings reset.